BioSpace News Archive

IGM Biosciences, Inc. today announced that Fred Schwarzer, Chief Executive Officer, will participate in a panel discussion on bispecific therapies at the Canaccord Genuity Horizons in Oncology Virtual Event on Wednesday, April 8 at 10:15 a.m. ET. A live webcast of the event will be available on the “Events and Present

New Test Immediately Available to Increase Capacity of Rapid, On-Site Testing of COVID-19 at Hospitals Across the U.S.

Express Scripts is supporting members through the COVID-19 pandemic by working with SilverCloud Health to make their digital mental health platform available to clients and their members at no cost.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update regarding the company’s business operations during the COVID-19 pandemic as part of its commitment to prioritize the safety, health and well-being of patients, their caregivers, healthcare providers and employees.

Hydrite® Chemical Co., an integrated manufacturer and supplier of chemicals and related services, is donating a specially formulated hand sanitizer to support hospitals, healthcare workers and facilities, and food banks in local communities as they respond to the COVID-19 global pandemic.

AADvac1 has a disease-modifying effect on Alzheimer’s Disease, evidenced by a combination of several biomarkers and clinical outcomes, most pronounced among younger patients;

KOR Life Sciences, a subsidiary of Vikor Scientific, has announced that Dr. Saeed Khan will join its new innovative biopharmaceutical company in Charleston, SC, as President of Research and Development.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees options to purchase an aggregate of 286,000 shares of BioCryst common stock on March 31, 2020 as inducements material to each employee entering into employment with BioCryst.

Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV: EMH; OTCQX: EMHTF) announced that its Pure Sunfarms (“PSF”) joint venture has finalized the expansion of its credit facility with its existing lender to $59 million, including accordion provisions of $22.5 million. The expanded credit facility (the “Credit Facility”) consists of a $7.5 million revolving operating loan (the “Revolver”) and a $10 million term loan (the “New Term L

BrainStorm Cell Therapeutics Inc. announced that its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded a new grant of approximately $1.5 million by the Israel Innovation Authority.